Breast Neoplasms, Fertility Preservation, Pregnancy
Conditions
Keywords
breast neoplasms, fertility preservation, pregnancy
Brief summary
The PREgnancy and FERtility (PREFER) study is a comprehensive program aiming to optimize care and improve knowledge around the topics of fertility preservation and pregnancy issues in young breast cancer patients. The program was initiated at the National Institute for Cancer Research, IRCCS AOU San Martino - IST in Genova (Liguria Region, Italy) and then it has been spread to other Italian Institutions under the umbrella of the Gruppo Italiano Mammella (GIM) study group. It is composed of two distinctive studies, one assessing fertility (i.e. PREFER-FERTILITY) and the other pregnancy (PREFER-PREGNANCY) issues. Hence, two different study protocols were developed under the umbrella of the PREFER registry. PREFER-FERTILITY aims to obtain and centralize data about the preferences and choices of young cancer patients on the fertility preservation strategies available in Italy. Furthermore, it aims to assess the outcomes of patients undergoing one or more strategies for fertility preservation in terms of success of the techniques (i.e. recovery of ovarian function, number of cryopreserved oocytes, post-treatment pregnancies) and safety (i.e. long-term survival outcomes). PREFER-PREGNANCY has two main objectives: 1) to obtain and centralize data on the management of breast cancer diagnosed during pregnancy, the obstetrical and paediatric care of children born after prior in utero exposure to anticancer treatments, and the long-term survival outcomes of these patients; 2) to obtain and centralize data on the clinical outcomes of breast cancer survivors that achieve a pregnancy after prior diagnosis and treatment of breast cancer.
Interventions
None listed
Sponsors
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Clinical Research Technology S.r.l.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* breast cancer diagnosis * age between18 and 45 years (only for PREFER-FERTILITY) * have not received any radiation or chemotherapy for cancer before enrolment (only for PREFER-FERTILITY) * absence of metastatic disease (only for PREFER-FERTILITY) * diagnosis of breast cancer during pregnancy or within 1 year from the end of pregnancy or pregnancy after prior diagnosis and treatment for breast cancer (only for PREFER-PREGNANCY) * informed consent
Exclusion criteria
* inability to provide written informed consent * stage IV disease at diagnosis (only for PREFER-FERTILITY) * serious psychiatric disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of patients interested in the available strategies for fertility preservation | 15 years | Assessed through medical records |
| Rate of patients undergoing the different strategies for fertility preservation | 15 years | Assessed through medical records |
| Type of strategies for fertility preservation proposed by oncologists | 15 years | Assessed through medical records |
| Reasons for refusal of the available strategies for fertility preservation | 15 years | Assessed through an open questionnaire |
| Type of anticancer therapies administered during pregnancy | 15 years | Assessed through medical records |
| Safety: pregnancy complications | 15 years | Assessed through medical records |
| Safety: incidence of adverse events | 15 years | Assessed through medical records |
| Disease-free survival | 15 years | — |
| Overall survival | 15 years | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Success of the available strategies for fertility preservation: rate of recovery of ovarian function after antitumor treatments | 15 years | — |
| Success of the available strategies for fertility preservation: number of oocytes collected and cryopreserved | 15 years | — |
| Success of the available strategies for fertility preservation: number of pregnancies achieved after breast cancer treatments | 15 years | — |
| Serum hormonal changes during chemotherapy and study follow up | 15 years | FSH (follicle stimulating hormone), estradiol and AMH (anti-mullerian hormone) serum levels assessed at baseline, during chemotherapy, at the end of chemotherapy and every six months thereafter |
| Obstetrical and paediatric care of children born after prior in utero exposure to anticancer treatments | 15 years | Assessed using obstetric and paediatric medical records |
| Obstetrical and paediatric care of children born in breast cancer survivors | 15 years | Assessed using obstetric and paediatric medical records |
Countries
Italy
Contacts
CONTACTLucia Del Mastro, MD
Outcome results
None listed